1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

ASH 2016 Preview: Don't Miss These 10 Data Presentations

 
• By Lucie Ellis-Taitt

A CAR-T late breaker from Kite Pharma and sickle cell disease updates from recently acquired Oklahoma biotech, Selxys, lead Scrip's handpicked top 10 data presentations you shouldn't miss at this year's American Society for Hematology annual meeting, held in San Diego, Dec. 2-6.

The American Society for Hematology's annual meeting kicks off on Dec. 2; to get you ready for attending this year's meeting or to help you know what to lookout for online, Scrip has selected 10 of the most exciting data readouts expected at the San Diego-based event.

Kite Pharma Inc. has managed to overtake Selexys Pharmaceuticals Corp. as the most anticipated company to present data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Nanobiotix/J&J Early Melanoma Data Show Potential For Future Indication

 
• By Mandy Jackson

Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.

Vepdegestrant Up For Grabs As Pfizer And Arvinas Step Aside

 
• By Manas Mishra

Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.

China’s Therapeutic mRNA Vaccine Pipeline For Oncology The Largest Globally

 
• By Xu Hu

Nearly half of the mRNA-based therapeutic vaccines for cancer in the R&D pipeline globally are from Chinese companies, although financing activities in the area have been relatively quiet so far this year in China compared with 2020-23.

Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC

 
• By Dexter Jie Yan

With data generated from China-only trials and consistency issues lingering, Chinese drug makers presented impressive results from early-stage studies of their assets at the World Conference on Lung Cancer annual conference.

More from Therapy Areas

Incyte’s Povorcitinib Wins Stack Up, Will It Be Enough To Hedge Jakafi Loss?

 
• By Aakash Babu

With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.

Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP

 
• By Alaric DeArment

The company announced positive Phase III data for the drug in fibrodysplasia ossificans progressiva, as well as Phase II combination data among patients with obesity.

Roivant Sets The Stage For Commercial Return With Brepocitinib Data

 
• By Jessica Merrill

Positive Phase III data positions Roivant to launch the oral TYK2/JAK1 inhibitor for dermatomyositis, with an NDA filing planned in early 2026.